Purpose. P128, a phage-derived lysin, exerts antibacterial activity on staphylococci by cleaving the pentaglycine-bridge of peptidoglycan. We sought to determine whether the presence of P128 could re-sensitize drug-resistant bacteria to antibiotics by virtue of its cell wall degrading property.
INTRODUCTION
Staphylococcus aureus/MRSA and coagulase-negative staphylococci (CoNS) are the leading cause of skin and skin structure infections, infective endocarditis (IE), foreign body-related infections (FBRI) and bacteraemia in humans [1, 2] . A large percentage of MRSA and CoNS strains have become resistant to a variety of antibiotics including those recently introduced into clinical use [3] [4] [5] [6] . Staphylococcal infections involving biofilms, e.g. IE and FBRI, are difficult to treat, require a long duration of treatment and are often recurrent in nature [7] . The complexities in treatment of these infections were thought to arise from the recalcitrant nature of biofilms to antibiotics [8] [9] [10] . A large majority of standard-of-care (SoC) antibiotics are known to be ineffective on staphylococcal biofilms in vitro [11] . Hence, there is an unmet medical need for antibiotics that can inhibit drug-resistant staphylococci, especially when the bacteria are growing on a biofilm. Strategies focused on discovering anti-biofilm agents against S. aureus have recently been reviewed [12] . In addition, multiple strategies to re-sensitize bacteria to antibiotics to which they have already become resistant are being explored. Strategies include suppressing the efflux mechanisms [13] and combination strategies that allow drug combinations to be effective against drug-resistant isolates [14] .
Because of the difficulties in treating MRSA infections, restoring b-lactam sensitivity in MRSA strains could have substantial clinical impact. A number of studies have reported successful restoration of oxacillin sensitivity to MRSA strains by treatment with oxacillin in combination with inhibitors of cell wall metabolism pathways. Using an anti-sense approach, Lee et al. [15] identified several genes coding for enzymes involved in cell wall biosynthesis whose knockdown would lead to hypersensitization to b-lactams. An inhibitor of one such protein, GlmS, was shown to potentiate the effect of b-lactams on MRSA strains [15] .
Inhibitors of proteins involved in the wall teichoic acid (WTA) biosynthesis pathway have also been shown to be synergistic with b-lactams, by sensitizing MRSA strains to b-lactams [16, 17] . Thus, in the presence of inhibitors of TarO and TarQ, proteins of the WTA biosynthesis pathway, MRSA strains became susceptible to b-lactam antibiotics [16, 17] . Thioridazine, an anti-psychotic drug, has been shown to restore b-lactam sensitivity in MRSA strains by reducing the transcription of mecA and blaZ genes [18] . A combination of oxacillin and lysostaphin was shown to be synergistic on oxacillin-resistant S. epidermidis (ORSE) strains in vitro, and to be efficacious in a rabbit model of infective endocarditis [19] . Climo et al. [20] also demonstrated that the combination of lysostaphin and nafcillin could significantly reduce c.f.u. in a rabbit model of endocarditis, as well as suppressing the emergence of lysostaphin-resistant mutants in vivo.
Phage-derived lysins, both endolysins and ectolysins, have emerged as potential alternative therapeutics for treating infections caused by drug-resistant pathogens [21] [22] [23] . Rapid bactericidal activity, specificity, potent anti-biofilm activity and low propensity toward the development of resistance make lysins promising candidates for clinical development [24] [25] [26] [27] . P128 is a phage K-derived chimeric recombinant ectolysin (a lysin involved in cleaving the bacterial peptidoglycan from outside the bacterium during phage DNA injection) that has shown potent and rapid bactericidal activity on sensitive and resistant clinical strains of S. aureus and CoNS [24] . P128 has shown potent anti-biofilm activity on preformed biofilms of both MRSA and clinically important species of CoNS such as S. epidermidis, S. haemolyticus and S. lugdunensis [26] [27] [28] . Importantly, P128 shows a high degree of synergy with various classes of SoC antibiotics in planktonic cells and biofilms [26, 27] .
In this study, we analysed the ability of P128 to re-sensitize drug-resistant staphylococci to specific antibiotics by testing the synergy of P128 in combination with a number of SoC drugs on planktonic cells and biofilms of drug-resistant S. aureus and CoNS. Confirmatory testing of the synergistic action observed in chequerboard assays was conducted in time-kill assays, and a combination of sub-therapeutic doses of P128 and oxacillin was tested for its ability to rescue mice from fatal MRSA infection.
METHODS

Materials
The sources of chemicals, reagents and antibiotics used in this study are listed in Table S1 (available in the online version of this article). P128 was purified from an E. coli overexpression strain as described previously [24] .
Strains and culture conditions
The strains used in this study are listed in Table 1 . S. aureus and CoNS cultures were routinely grown in trypticase soy broth (TSB), Luria-Bertani (LB) broth or agar at 37 C.
MIC, MBC and synergy on planktonic cells
The MIC of P128 and SoC drugs was determined using a modified Clinical and Laboratory Standards Institute (CLSI) broth microdilution procedure [29] . Briefly, microtitre plate wells were pre-coated with 0.5 % bovine serum albumin (BSA) to prevent non-specific binding of P128 to the polystyrene plate. Two-fold dilutions of P128 were prepared in cation-adjusted Mueller-Hinton broth (CAMHB), and 50 µl aliquots of diluted P128 (0.125-256 µg ml À1 ) were added to the microtitre plate wells. Bacterial suspensions (0.5 McFarland standards) were diluted in CAMHB to achieve 1Â10 6 colony-forming units (c.f.u.) per ml and 50 µl aliquots of the cell suspension were added to the plate wells containing P128. The plates were incubated under static conditions at 35 C for 18 h. The MIC was defined as the lowest concentration of P128 or the antibiotic in which no visible growth was observed at the end of the incubation period. The MBC was determined using the CLSI procedure [30] . Briefly, 100 µl from the MIC, twofold MIC (2Â MIC), fourfold MIC (4Â MIC) and eightfold MIC (8Â MIC) wells were plated on LB agar and incubated at 37 C overnight. The MBC was defined as the lowest concentration of P128 causing >3 log c.f.u. reduction under the assay conditions.
The synergistic inhibition of planktonic cells of S. aureus and CoNS by combinations of P128 and SoC antibiotics was assessed by the microdilution chequerboard technique described previously [26, 31] . Briefly, 50 µl of an S. aureus or CoNS culture at a final density of 5Â10 5 c.f.u. ml À1 in CAMHB was added to wells of 96-well microtitre plates pre-coated with 0.5 % BSA and containing twofold dilutions of P128 (25 µl) and/or an antibiotic (25 µl) in CAMHB. The CAMHB was supplemented with 50 µg ml À1 Ca 2+ (as CaCl 2 ) when testing daptomycin combinations. The microtitre plates were incubated at 35 C for 18 h, and the individual MICs and combination MICs were read. The fractional inhibitory concentration index (FICI) was determined using the following equation: FICI = (MIC of drug A in the combination/MIC of drug A alone) + (MIC of drug B in the combination/MIC of drug B alone). The combination was considered to be synergistic when the FICI was 0.5; additive when FICI was 0.5-1.0; indifferent when FICI was 1-4; and antagonistic when FICI was !4. The experiments were performed in triplicate.
Time-kill kinetics
Bacterial strains were grown in CAMHB to a density of approximately 1Â10 8 c.f.u. ml À1 and diluted in CAMHB to obtain a cell density corresponding to 5Â10 5 c.f.u. ml
À1
. Aliquots (2.7 ml) of cell suspension were dispensed in glass vials and 300 µl of the individual drug, or 150 µl of each drug when tested in combination, were added to the tubes. The vials were incubated at 37 C with shaking at 200 r.p.m., and 300 µl samples were withdrawn at stipulated time points (15 min, 1, 2, 4, 8 and 24 h) to assess the viability of the cultures. The samples were serially log diluted and plated on LB plates. To determine synergy in killing, P128 and drugs (oxacillin or vancomycin) were tested at concentrations at which P128 or individual drugs showed minimal killing. A difference of greater than 2 log 10 in killing observed between a combination and the most active single drug was considered as synergistic killing.
Minimum biofilm inhibitory concentration (MBIC) and synergy of P128 with antibiotics The MBIC of P128 and antibiotics on S. aureus or CoNS strains was determined by the procedure described previously [26] . Briefly, an overnight-grown bacterial culture was diluted 1 : 40 in LB broth and 200 µl of the diluted culture was aliquoted into microtitre plate wells. The plates were placed in a shaker-incubator at 37 C and 100 r.p.m. for 24 h followed by 48 h incubation under static conditions at 37 C to allow biofilm formation. The supernates from the plate wells were aspirated out and discarded. The wells were washed twice with 1Â PBS and the biofilm formation in the wells was quantified by the metabolic dye-reduction assay method using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). In this assay, the colour formation upon reduction of the dye by living cells can be read at 570 nm, and the intensity of colour can be correlated to the number of live cells [26] . After washing the biofilm, 100 µl of PBS was added to the wells along with 10 µl of MTT solution and the plate was incubated for 2 h in the dark. Post-incubation, 110 µl of solvent solution (solubilizing agent) was added to the plate wells and the plate was further incubated for 15 min at ambient temperature with gentle agitation. The absorbance was read at 570 nm in a microplate reader.
For biofilm inhibitory studies, the biofilm-containing wells were washed twice with 1x PBS and challenged with various concentrations of P128 or the drugs in LB and incubated for 6 h at 37 C. LB was supplemented with 50 µg ml À1 CaCl 2 for daptomycin and 2 % NaCl for oxacillin treatment wells, respectively. After treatment, the supernate was aspirated out and discarded. The biofilm adhering to the wells was quantified by MTT assay as described above. The MBIC was defined as the minimum concentration of P128 or the drug showing no colour development. In order to determine whether P128 showed synergy with other drugs, combinations of P128 and antibiotics were tested by the microdilution chequerboard method described previously [26] . For comparison, the MBIC of each drug was also determined individually in each experiment. The fractional MBIC concentrations were determined by MTT dye assay as described above. The FICI and synergy were also calculated by the formula described above for synergy in planktonic cells.
Disruption of biofilms by P128 and SoC antibiotics: scanning electron microscopy (SEM) An overnight-grown culture was diluted 1 : 40 in trypticase soy broth (TSB) containing 5 % rabbit plasma for S. aureus and 4 % NaCl for S. epidermidis. Two-centimetre catheter (JMS Infusion set) pieces were cut and sliced longitudinally in two halves. The sliced catheter pieces were added to the culture and incubated at 37 C with shaking at 100 r.p.m. for 24 h. Post-incubation, the catheter pieces were removed and rinsed twice in PBS to remove the adherent planktonic cells. The biofilms on these catheters were challenged with P128 or one of the antibiotics or with a combination of P128 and antibiotics at sub-inhibitory concentrations by transferring the catheter pieces into tubes containing the drugs in TSB. The tubes were incubated at 37 C under static conditions for 18 h. The catheters were then rinsed once in PBS and immersed in 0.1 % safranin for 5 min. The stained catheters were washed once in PBS and allowed to dry. For scanning electron microscopy (SEM), the dried samples were fixed on aluminum stubs with double-sided carbon adhesive tape, coated with 5-7 nm gold or silver by use of a sputter-coating system (Q150T; Quorum Technologies) and examined by SEM (Neon 40; Carl-Zeiss) for the presence of biofilm structures.
Bactericidal effect of P128 and drug combinations on biofilms of MRSA and VRSA strains on the surface of catheters In order to assess the bactericidal effect of P128 or drug combinations on biofilms by c.f.u. drop assay, biofilms were grown on the surface of catheters as described above. The biofilm-carrying catheters were treated with P128 and oxacillin or vancomycin individually or in combination for 18 h. Thereafter, the catheters were removed from the tubes, rinsed twice in PBS and placed in Eppendorf tubes containing 1 ml of PBS. To release the adherent biofilm into PBS, the catheters were scraped using an inoculation loop. The samples were vortexed thoroughly and appropriate dilutions were plated on LB agar plates and incubated at 37 C for 18-20 h.
Efficacy of P128 and oxacillin combination on a MRSA strain in a mouse model of bacteraemia All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Ethics Committee of GangaGen Biotechnologies Pvt Ltd. Female BALB/c mice 8-9 weeks old weighing 20-25 g were used for the study. The animals were housed in individually ventilated cages with free access to water, fed ad libitum and maintained under a 12 : 12 h light:dark cycle at [19] [20] [21] C. Colonies of the MRSA USA300 strain from LB agar plates were resuspended in LB broth and grown for 3 h at 37 C/120 r.p.m. in a shaker-incubator. Bacterial lawns were prepared from these cultures on nutrient agar plates containing 5 % sheep blood. The lawn cultures were harvested, suspended in sterile saline and centrifuged. The cell pellets were washed three times with sterile saline and the optical density at 600 nm (OD 600 ) of the cell suspension was adjusted to obtain a final cell concentration of 2.5±0.5Â10 10 c.f.u. ml À1 in 5 % (v/v) porcine mucin (Sigma Aldrich). Data from preliminary experiments suggested that a challenge dose of 10 9 c.f.u. per animal resulted in 80-100 % mortality (LD 80-100 ) by 72 h. Mice were challenged with~10 9 c.f.u. per animal in a volume of 200 µl by intraperitoneal (IP) injection. Two hours post-infection, animals were treated with sub-therapeutic doses of P128 or oxacillin: a single dose of P128 at 2.5 mg kg À1 IP, or four doses of 100 mg kg À1 oxacillin, a short serum half-life b-lactam [32] injected intramuscularly at 4 h intervals. To evaluate the efficacy of the two drugs in combination, one group of animals was treated with both P128 and oxacillin. Survival of the animals was monitored up to 72 h post-infection.
Statistical analysis
To determine the statistical significance of the difference observed between two values, the one-way analysis of variance (ANOVA) test was applied and a P-values of <0.05 were considered significant.
RESULTS
In order to determine whether P128 could re-sensitize bacteria to clinically relevant classes of anti-Staphylococcus drugs, we tested P128 on planktonic cells and biofilms of drug-resistant strains of S. aureus and S. epidermidis (see Table 1 for the list of strains), in combination with a number of antibiotics with different mechanisms of action.
P128 reverses the resistance phenotype of drug-resistant S. aureus and S. epidermidis strains The data showing inhibition of S. aureus and S. epidermidis strains in chequerboard assays using sub-MIC concentrations of P128 and various antibiotics are shown in Table 2 . The MIC of P128 on these strains varied from 0.45 to 32 µg ml
À1
. Individual MICs of oxacillin, cephazolin, vancomycin, daptomycin, linezolid and ciprofloxacin were found to be several fold higher than the clinical sensitivity cut-off values, confirming the drug resistance phenotype of these strains. In all combinations and in all of the strains, a combination of sub-MIC P128 and an antibiotic at a concentration within its clinical sensitivity range could inhibit the growth of bacteria in a synergistic manner. For example, in the case of VRSA strains, a combination of 0.24-0.48 µg ml À1 of P128 and 0.25-2.0 µg ml À1 of vancomycin could inhibit the growth of the bacteria. In MRSA and MRSE isolates, the presence of sub-MIC (0.025-4 µg ml À1 ) P128 reduced the inhibitory concentration of oxacillin to well within the clinical sensitivity range recommended for S. aureus strains (<1.0 µg ml À1 ; Table 2 ). A similar synergistic effect was seen in MRSA strains in combination with sub-MIC P128 and cephazolin. The effect was not restricted to cell wall metabolism-inhibiting drugs, but was also observed with daptomycin, linezolid and ciprofloxacin on strains of S. aureus and S. epidermidis resistant to the corresponding drugs (Tables 1  and 2 ). The only exception was S. aureus BK1, which required 8 µg ml À1 of ciprofloxacin in combination with 0.25 µg ml À1 of P128 for growth inhibition. The FIC values in P128 and antibiotic combinations were found to range from 0.05 to 0.50, suggesting a high degree of synergy. Though a low FICI in the majority of the P128 and antibiotic combinations suggested good synergy, a FICI of <0.10 in three strains in a combination of P128 and oxacillin pointed towards relatively better synergy in this combination. , after an initial 2 h c.f.u. reduction, allowed bacteria to grow normally and the OD 600 of the treated culture at 24 h was similar to that of the untreated culture control (Fig. 1a) . The combination of P128 at 0.03 µg ml À1 and oxacillin at 1 or 2 µg ml À1 caused almost complete killing of the culture and did not allow regrowth through the final 24 h time point, demonstrating the superiority of the combination in killing this MRSA strain.
As shown in Fig. 1b , sub-MIC concentrations of vancomycin (1 and 2 µg ml À1 ) on VRSA B9455 allowed the bacteria to grow, albeit at a slower rate than the cell control. P128 at 0.015 µg ml À1 caused an initial drop in c.f.u. that was maintained through the 2 h time point, but the bacteria started growing after this time point and at 24 h the OD 600 was comparable to that of the vancomycin-treated cultures. The combination of P128 and vancomycin at these sub-MIC concentrations, however, reduced the c.f.u. by more than 4 log in 8 h, and no regrowth was visible in treated cultures through the final 24 h time point.
Thus, for both MRSA and VRSA, the addition of P128 to the standard antibiotic resulted in rapid, near-complete eradication of the bacteria in the culture. Both of the TKK experiments suggested that P128 in combination with SoC drugs is highly bactericidal on drug-resistant S. aureus isolates.
P128 can re-sensitize biofilms of drug-resistant S. aureus and S. epidermidis to various SoC antibiotics Biofilms of even sensitive strains of bacteria are known to be phenotypically tolerant to the action of antibiotics [11] . Hence, the MBICs of most of the SoC antibiotics on staphylococcal biofilms are much higher than the MIC values on planktonic cells [26, 27] . In order to determine whether a P128-mediated drug re-sensitization effect would be seen even on biofilms, we conducted P128 and SoC antibiotics synergy assays by the chequerboard method on S. aureus and S. epidermidis resistant to various drugs. The MBICs of all drugs except daptomycin were >125 µg ml À1 on drugresistant strains of S. aureus and S. epidermidis (Table 3) . As expected, the MBIC of P128 was 4-8 µg ml À1 on the majority of the strains, although it was as high as 105 µg ml À1 on one ciprofloxacin-resistant strain. On MRSA MW2, the MBIC of oxacillin and cephazolin was >250 µg ml À1 ; in combination with sub-MBIC P128, however, the MBIC of oxacillin and cephazolin was reduced to 0.24 and 3.9, respectively. On the two daptomycin-resistant S. epidermidis strains, although daptomycin had a relatively modest MBIC, the addition of P128 reduced it further and the combination of P128 and SoC antibiotics markedly reduced the antibiotic MBICs in all strains ( Tables 2 and 3 ) and the shapes of isobolograms (Fig. S1 ), suggest that P128 and drug combinations showed equal or better synergy on biofilms than on planktonic cells.
SEM studies: removal of biofilm biomass of drug-resistant isolates on catheters by P128 and antibiotic combinations Removal of biofilm biomass of MRSA, VRSA, LRSA and DRSE strains by P128, SoC drugs and combinations of two agents was studied by safranin staining and scanning electron microscopy (SEM) of preformed biofilms on the surface of catheters. In the MRSA MW2 strain, while oxacillin at 5-10 µg ml À1 had no significant effect on biofilm biomass and P128 at 1 µg ml À1 (sub-MBIC) disrupted the biofilm to some extent, the majority of the biomass could still be observed (Figs 2a and S2) .The combination of sub-MIC P128 and oxacillin, on the other hand, disrupted the biofilms completely and no staphylococci could be seen in treated samples by SEM (Fig. 2a) . Safranin-stained catheter samples showed that vancomycin at 30 µg ml À1 did not have an appreciable effect on biofilm biomass of the VRSA isolate, while 0.5 µg ml À1 P128 appeared to have removed some of the biomass (Fig. S2) . However, under SEM, P128 at 0.5 µg ml À1 did not seem to affect the appearance of biofilm appreciably (Fig. 2b) . Notably, the combination of sub-MIC P128 and vancomycin disrupted the biofilms completely and no biomass was observed by either safranin staining or SEM (Figs 2b and S2 ). Similar observations were made with LRSA and DRSE strains, wherein sub-MBIC concentrations of P128 or SoC drugs did not affect the biomass appreciably whereas P128 and drug combinations were very effective in removing biomass (Fig. 2c, d ). This demonstrated that combinations of P128 and SoC drugs at sub-MBIC concentrations could efficiently disrupt the biofilms of drug-resistant strains.
Sub-MBIC concentrations of antibiotics in combination with P128 have a bactericidal effect on biofilms
In order to determine whether the P128-mediated phenotypic reversal of oxacillin or vancomycin resistance and its synergistic effect observed on biofilms of MRSA, VRSA, DRSE and LRSA strains could lead to killing of biofilmembedded bacterial cells, biofilms on the surface of catheters were treated with sub-MBIC concentrations of P128 and oxacillin, vancomycin, daptomycin or linezolid individually and in combination. P128 at 1 µg ml À1 and oxacillin at 1 or 2 µg ml À1 hardly caused any loss of viability in MW2 MRSA biofilms when used individually (Fig. 3a) . The combination of P128 and oxacillin at the same concentration could reduce the c.f.u. load by more than three orders of magnitude (Fig. 3a) . Similarly, treatment of VRSA B9455 biofilms with P128 at 0.05 µg ml À1 and vancomycin at 15 or 30 µg ml À1 did not result in an appreciable reduction in c.f.u. (Fig. 3b) . However, the combination of P128 and vancomycin at similar concentrations could reduce the c.f.u. load by two to three orders of magnitude (Fig. 3b) . A potent bactericidal effect was also seen in the combination of P128 with daptomycin and linezolid on DRSE and LRSA strains, respectively (Fig. 3c, d ) This demonstrated that P128 and SoC drugs are synergistic in killing bacterial cells on the biofilms of drug-resistant S. aureus and S. epidermidis cultures.
The combination of sub-therapeutic doses of P128 and oxacillin is efficacious in a MRSA model of bacteraemia In order to determine whether the re-sensitization effect of P128 seen on MRSA strains in vitro would translate to efficacy in an animal model, we tested the efficacy of P128 and oxacillin on a strain of MRSA in a mouse model of bacteraemia. Infection conditions in mice were established to obtain >80 % mortality within 24 h. Sub-therapeutic doses of oxacillin (100 mg kg
À1
) and P128 (2.5 mg kg
) and the combination of oxacillin and P128 were tested in the mouse model by measuring mortality/survival as an endpoint. The untreated animals showed >80 % mortality within 12 h (Fig. 4) . Oxacillin at 100 mg kg À1 and P128 at 2.5 mg kg
could protect 31 and 50 % of the animals, respectively. The combination of P128 and oxacillin protected 81 % of the animals through the final 72 h time point, showing that this combination was superior to the individual drugs at these doses.
DISCUSSION
There is an urgent need to discover new therapies for treating infections caused by drug-resistant staphylococci, including MRSA and CoNS. In addition to the conventional approach of discovering novel antibiotics, strategies focusing on restoring the sensitivities of strains to the drugs to which they have become resistant have the potential to help control serious infections [13, 14] . In this study, we demonstrated that P128, which shows potent bactericidal effect on staphylococci by cleaving the pentaglycine bridge of peptidoglycan [33] , can reverse the drug resistance phenotype of a variety of staphylococci. The re-sensitization effect and synergistic inhibition were observed in all combinations of P128 and SoC drugs on all drug-resistant strains of S. aureus and CoNS tested. On planktonic cells a combination of P128 and SoC drugs, in most cases, reduced the MIC of standard antibiotics to a level where a strain would be classified as sensitive. In cultures treated with a combination of sub-MIC P128 plus oxacillin or vancomycin, not only were the bacteria almost eradicated, but the regrowth associated with low concentrations of P128 was completely prevented through the final 24 h time point (Fig. 1) .
The low FIC indices in P128 and SoC drug combinations in MRSA and VRSA planktonic cells and biofilms suggest that the combination therapy has the potential to restore the clinical utility of b-lactams and vancomycin on the respective drug-resistant isolates in serious infections involving biofilms such as IE and FBRI. It is noteworthy that the extent of synergy between P128 and SoC antibiotics was significantly higher in biofilms than in planktonic cells, as evidenced by lower FIC indices (Tables 2 and 3 ) and the shapes of curves in isobolograms (Fig. S1) . Importantly, the synergistic effect of P128 and SoC drugs was not merely inhibitory, but also led to the killing of biofilm-embedded MRSA, VRSA, LRSA and DRSE cells. Because the synergistic effect is not restricted to a particular class of antibiotics, it is possible that the P128-mediated increase in cell wall permeability of staphylococci plays a role in re-sensitizing bacteria to antibiotics. The synergistic killing of MRSA strains by a combination of oxacillin and P128 is also consistent with earlier findings using a combination of lysostaphin with oxacillin or nafcillin [20] . The restoration of b-lactam sensitivity in S. aureus by using small molecule inhibitors of WTA or thioridazine has been reported [15-18, 34, 35] . A combination of b-lactam with both lysostaphin and a phage lysin, ClyS, has also been shown to be synergistically effective on MRSA strains in vitro and in vivo [20, 36] . It has been postulated that MRSA strains are highly vulnerable to potentiation of b-lactams by cell wall inhibitors as compared to other non-b-lactam classes of drugs [15] . We found the P128 and oxacillin combination to be marginally superior to other SoC drugs in synergistic inhibition of antibiotic-resistant strains. The synergistic effect of PC190723, a FtsZ inhibitor, and b-lactams has been attributed to concomitant de-localization of the drug targets, FtsZ and PBP2 [37] . It is likely that synergistic killing of MRSA by low concentrations of P128 and oxacillin might result from similar effects, but evidence to support this notion is currently lacking. Also, the synergistic inhibition of drug-resistant strains by a combination of P128 and other SoC drugs might result from a different mechanism, which needs to be investigated. The enhanced synergy seen in biofilms compared to planktonic cells could have resulted from the ability of P128 to kill non-growing persisters [27] , which are known to be abundant in biofilms and are thought be responsible for the high level of resistance of S. aureus biofilm to antibiotics [38] . The synergistic effect was also clearly demonstrated in the mouse model of bacteraemia, wherein sub-therapeutic doses of P128 and oxacillin were individually only partially effective in rescuing animals, whereas the drug combination allowed more than 80 % of the animals to survive. Based on these data, the combination of P128 with other SoC drugs that show synergy in vitro would also be expected to result in in vivo efficacy in animal models, and would be a fruitful area for additional research.
The approach of combining two antibacterials, instead of an antibiotic adjuvant combination, has the advantage of better bactericidal effect and potent efficacy on biofilms. Earlier studies were focused on the use of b-lactam combinations on MRSA. In this study, we have tested a number of other antibiotics in combination with P128 on a variety of drugresistant strains of S. aureus (MRSA, VRSA, LRSA, etc.) and S. epidermidis (MRSE and DRSE). To our knowledge, this is the first report demonstrating the re-sensitization effect and synergy of a lysin and antibiotics in preformed biofilms of drug-resistant strains of S. aureus and S. epidermidis. This is particularly relevant because it is crucial for a drug to be efficacious on biofilms in order to successfully reduce the duration of treatment and prevent relapses. More animal efficacy studies are required to determine the optimal doses of P128 and SoC combinations that will prove to be efficacious on drug-resistant strains. Additionally, in vivo combination efficacy studies need to be performed with other SoC drugs currently used such as daptomycin, vancomycin and linezolid, to confirm that in vitro synergistic killing can be translated into efficacy in animal models. The ability of P128 to re-sensitize resistant staphylococci to SoC antibiotics suggests that combinations of P128 and these drugs can be developed to treat infections caused by drug-resistant staphylococci.
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